p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas

Blood

Volumn 91, Issue 8, 1998, Pages 2977-2984

  Pinyol, Magda ^a   Cobo, Francesc ^a   Bea, Silvia ^a   Jares, Pedro ^a   Nayach, Iracema ^a   Fernandez, Pedro L ^a   Montserrat, Emilio ^a   Cardesa, Antonio ^a   Campo, Elias ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P16;

ARTICLE; DNA METHYLATION; DNA SEQUENCE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0032523043     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.2977.2977_2977_2984     Document Type: Article

References (50)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson P, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri S, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361, 1994
2. Robertson L, Pugh W, O'Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating M: Richter's syndrome: A report of 39 patients. J Clin Oncol 11:1985, 1993
3. Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumonet C, Bryon P, Coiffer B: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587, 1997
4. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen, Anderson JR, Weisenburger DD: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302, 1996
5. Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZ, Lister TA: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6:249, 1995
6. Imamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412, 1994
7. Gaidano G, Ballerini P, Gong J, Inghirami G, Neri A, Newcomb E, Magrath I, Knowles D, Dalla-Favera R: p53 mutations in human lymphoid malignances associated with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
8. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R: p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 82:2289, 1993
9. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994, 1993
10. Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA, Piris MA, Montserrat E, Cardesa A, Jaffe ES, Campo E, Raffeld M: p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87:3351, 1996
11. Du M, Peng H, Singh N, Isaacson PG, Pan L: The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 86:4587, 1995
12. Hirama T, Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841, 1995
13. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79:573, 1994
14. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686, 1995
15. ink4 in human cancer. Proc Natl Acad Sci USA 91:11045, 1994
16. ink4b in non-Hodgkin's lymphomas. Blood 86:1534, 1995
17. Koduru PR, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD: Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p16 in non-Hodgkin's lymphoma. Blood 86:2900, 1995
18. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS: Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893, 1995
19. Martinez-Delgado B, Fernandez-Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J: Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 11:425, 1997
20. ink4a) gene in primary B-cell lymphomas. Blood 86:2724, 1995
21. wafl genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272, 1997
22. Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, Tassies D, Jaffe ES, Montserrat E, Rozman C, Cardesa A: Prad-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma. Blood 84:2726, 1994
23. Serrano M, Hannon GJ, Beach D: New regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704, 1993
24. ink4b/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436, 1995
25. Pollock PM, Pearson JV, Hayward NK: Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. Genes Chromosomes Cancer 15:77, 1996
26. Yano T, Jaffe ES, Longo DL, Raffeld M: Myc rearrangements in histologically progressed follicular lymphomas. Blood 80:758, 1992
27. Rechavi G, Katzir N, Brok-Simoni F, Holtzman F, Mandel M, Gurfinkel N, Givol D, Ben-Bassat I, Ramot B: A search for bc1-1, bc1-2, and c-myc oncogene rearrangement in chronic lymphocytic leukemia. Leukemia 3:57, 1989
28. ink4. Science 267:249, 1995
29. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavenee WK, Su Huang HJ: Loss of p16ink4 expression is frequent in high grade gliomas. Cancer Res 55:1941, 1995
30. ink4b/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448, 1995
31. Reed JA, Loganzo F Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW, Albino AP: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55:2713, 1995
32. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, De Pinho RA: Role of the ink4a locus in tumor suppression and cell mortality. Cell 85:27, 1996
33. ink4b) display frequent homozygous deletions in primary cells from T-but not from B-cell lineage acute lymphoblastic leukemias. Blood 84:4038, 1994
34. ink4a characterize the major types of hematological malignancies. Cancer Res 57:837, 1997
35. Okuda T, Shurtleff SA, Valentine MB, Raimondi SC, Head DR, Behm F, Curcio-Brint AM, Liu Q, Pui CH, Sherr CJ, Beach D, Look AT, Downing JR: Frequent deletion of p16ink4a/mts1 and p15ink4b/mts2 in pediatric acute lymphoblastic leukemia. Blood 85:2321, 1995
36. ink4 gene inactivation in acute lymphocytic leukemia. Blood 85:3431, 1995
37. Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JW, Reiter A, Ludwig WD, Zimmermann M, Schwaller J, Lee E, Miyoshi I, Koeffler HP: Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4b, p16/MTS1/INK4a, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 86:755, 1995
38. Fizzotti M, Cimino G, Pisegna S, Alimena G, Quartarone C, Mandelli F, Pelicci PG, Lo Coco F: Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood 85:2685, 1995
39. ink4b, p53, and Rb genes in primary lymphoid malignancies. Blood 87:4949, 1996
40. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Shimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Nobuhiko E, Yazaki Y, Ueda R, Hirai H: Loss of the cyclin-dependent kinase 4-inhibitor (p16;MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86:1548, 1995
41. Sill H, Goldman JM, Cross NC: Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013, 1995
42. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP: Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 85:2699, 1995
43. Matolcsy A, Inghirami G, Knowles DM: Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). Blood 83:1363, 1994
44. ink4b gene deletions in primary leukemias. Blood 86:311, 1995
45. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y: Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 86:1269, 1995
46. Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, Bauters F, Wattel E, Fenaux P: p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 85:657, 1995
47. ink4a tumor suppressor protein. Cancer Res 55:2503, 1995
48. Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutberland RC. Cancer-associated missense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 66:249, 1996
49. ink4a/MTS1) gene structure and expression in acute lymphoblastic leukemias. Leukemia 9:1240, 1995
50. Batova A, Diccianni MB, Yu JC, Nobori T, Link MP, Pullen J, Yu AL: Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 57:832, 1997